Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea
Phase 2
Completed
- Conditions
- Obstructive Sleep Apnea
- Registration Number
- NCT01186926
- Lead Sponsor
- Apnex Medical, Inc.
- Brief Summary
The overall goal of the study is to evaluate the safety, efficacy and therapy settings of the HGNS System for stimulating the hypoglossal nerve to help maintain an open airway in subjects with obstructive sleep apnea (OSA).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Mean change in AHI measured with in-lab nighttime polysomnography (PSG) compared to baseline 6 months post-implant Adverse event profile interoperatively, perioperatively, and long term post implant 1, 3, 6, 12, 24, and 36 months post implant
- Secondary Outcome Measures
Name Time Method Mean change in functional outcomes measured with the Functional Outcomes of Sleep Questionnaire (FOSQ) compared to baseline 6 months post-implant
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie hypoglossal nerve stimulation in OSA treatment?
How does the Apnex Medical HGNS System compare to CPAP in treating moderate to severe OSA?
Are there specific biomarkers that predict response to hypoglossal nerve stimulation therapy?
What are the potential adverse events associated with implantable HGNS devices and their management?
What combination therapies are being explored alongside hypoglossal nerve stimulation for OSA?